Compare CSX Corporation (CSX) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Eli Lilly And Co — how do they compare? CSX Corporation trades at $47.3 (market cap $87.70B), while Eli Lilly And Co trades at $1,177.57 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 11.9× CSX Corporation's market cap, and CSX Corporation pays the higher dividend (1.18%). Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Eli Lilly And Co for 93 Days on average.
| CSX | LLY | |
|---|---|---|
Market Cap | $87.70B | $1.04T |
Volume | 6,980,781 | 3,064,878 |
Sector | Industrials | Health |
52-Week High | $53.21 | $1.28K |
52-Week Low | $33.68 | $799.57 |
Typical Hold Time | 55 Days | 93 Days |
Enterprise Value | $105.66B | $1.09T |
Dividend Yield | 1.18% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.26, up 0.96% with a bullish technical signal. The stock shows strong profitability with 22.21% net margin and 24.37% ROE, though revenue declined to $14.09B in 2025. Recent Q2 2026 earnings beat expectations at $0.54 vs $0.518. Analyst consensus is bullish with 58.69% buy ratings and $51.00 price target. The company maintains stable cash flow operations and recently announced a $0.14 dividend payable September 2026.
CSX presents a favorable investment case with strong fundamentals and analyst support, though valuation metrics appear elevated. Key risks include revenue pressure and competitive threats. The upcoming Q3 2026 earnings on October 21 will be critical for confirming the positive trend. Current levels offer potential upside to consensus targets but require monitoring of operational execution.
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
